Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasma cell leukemia.

Literature DB >> 20442443

Plasma cell leukemia.

Moria A Gertz, Francis K Buadi.

Abstract

Entities: Disease

Mesh：

Year: 2010 PMID： 20442443 PMCID： PMC2864374 DOI： 10.3324/haematol.2009.021618

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

20 in total

1. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.

Authors: H Avet-Loiseau; A Daviet; C Brigaudeau; E Callet-Bauchu; C Terré; M Lafage-Pochitaloff; F Désangles; S Ramond; P Talmant; R Bataille
Journal: Blood Date: 2001-02-01 Impact factor: 22.113

2. Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme.

Authors: J J van Veen; J T Reilly; S J Richards; L Whitby; K Goodfellow; V Granger; D C Rees; D Barnett
Journal: Clin Lab Haematol Date: 2004-02

3. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

Authors: Eirini Katodritou; Evgenia Verrou; Vassiliki Gastari; Christina Hadjiaggelidou; Evangelos Terpos; Konstantinos Zervas
Journal: Leuk Res Date: 2008-02-20 Impact factor: 3.156

4. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.

Authors: Paolo Bernardeschi; Maria Teresa Pirrotta; Iolanda Montenora; Gloria Giustarini; Maria Immacolata Ferreri; Paolo Simi; Giammaria Fiorentini
Journal: Leuk Res Date: 2009-11-03 Impact factor: 3.156

5. Primary plasma cell leukemia and autologous stem cell transplantation.

Authors: Mary B Drake; Simona Iacobelli; Anja van Biezen; Curly Morris; Jane F Apperley; Dietger Niederwieser; Bo Björkstrand; Gösta Gahrton
Journal: Haematologica Date: 2010-05 Impact factor: 9.941

6. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.

Authors: R E Johnston; S H Abdalla
Journal: Leuk Lymphoma Date: 2002-02

7. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors: C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal: Leukemia Date: 1998-12 Impact factor: 11.528

8. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors:
Journal: Br J Haematol Date: 2003-06 Impact factor: 6.998

9. Efficacy and safety of bortezomib in patients with plasma cell leukemia.

Authors: Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Guglielmelli; Giovanni D'Arena; Felicetto Ferrara; Nunzio Filardi; Roberto Guariglia; Antonio Palumbo
Journal: Cancer Date: 2007-06-01 Impact factor: 6.860

10. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia.

Authors: Tommasina Guglielmelli; Roberta Merlini; Emilia Giugliano; Giuseppe Saglio
Journal: J Oncol Date: 2009 Impact factor: 4.375

3 in total